Debt to Equity Ratio: A measure of a company's financial leverage calculated by dividing its long-term debt by shareholders equity. Calculated as: Total Debt / Shareholders Equity
Aligos Therapeutics, Inc. (ALGS) had Debt to Equity Ratio of 0.00 for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$0.74M |
|
$-31.54M |
|
-- |
|
$0.74M |
|
$29.10M |
|
$-28.36M |
|
$-3.12M |
|
$-31.48M |
|
$-31.48M |
|
$-31.54M |
|
$-31.54M |
|
$-31.54M |
|
$-31.54M |
|
$-28.36M |
|
$-28.37M |
|
10.37M |
|
10.37M |
|
$-3.04 |
|
$-3.04 |
|
| Balance Sheet Financials | |
$103.44M |
|
$2.04M |
|
$6.33M |
|
$109.76M |
|
$21.99M |
|
$0.12M |
|
$15.94M |
|
$37.93M |
|
$71.83M |
|
$71.83M |
|
$71.83M |
|
6.15M |
|
| Cash Flow Statement Financials | |
$-60.76M |
|
$-35.80M |
|
$101.51M |
|
$37.11M |
|
$42.06M |
|
$4.95M |
|
$3.59M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.70 |
|
-- |
|
-- |
|
0.00 |
|
|
Debt to Equity Ratio |
0.00 |
100.00% |
|
-3827.40% |
|
-3827.40% |
|
-- |
|
-4248.45% |
|
-4256.01% |
|
$-61.10M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-43.90% |
|
-43.90% |
|
-28.73% |
|
-43.83% |
|
$11.67 |
|
$-5.89 |
|
$-5.86 |
|